Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine for Cisplatin/Paclitaxel Neurotoxicity
NCT00003624Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Dec 1998
- Primary completion
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in neurotoxicity, sponsored by GOG Foundation. Primary endpoint: Efficacy of amifostine in reducing significant peripheral neuropathy. Started Dec 1998; status: terminated.
02
Drugs
amifostine
03
Conditions
neurotoxicity
Beyond the preview
Go deeper on NCT00003624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003624.